HK Stock Market Move | SHINEWAY PHARM (02877) rises more than 4%, Peach Red Four Substances Decoction Granules approved for market. The company's classic formula research and development has entered a period of concentrated output.

SHINEWAY PHARM (02877) rose more than 4%, rising 4.55% as of press time to HK$10.33 with a turnover of HK$103.212 million. On the news front, according to SHINEWAY PHARM's official WeChat account, it has been officially approved by the National Medical Products Administration that Shenwei Taohong Siwu Tang (National Medicine Permit No. C20260009) has been approved for market launch. SHINEWAY PHARM has become the first enterprise in Hebei Province to obtain the approval number for this product. So far this year, SHINEWAY PHARM has obtained approvals for 3 classic prescriptions, continuing to enrich the group's classic prescription product matrix and accelerating the transformation of traditional Chinese medicine classic formulas into clinical productivity. Currently, SHINEWAY PHARM has obtained approvals for 7 classic prescriptions, maintaining the top position in the country. Currently, the company's research and development of classic prescriptions has entered a period of concentrated output, with product matrices covering multiple treatment areas such as respiratory, digestive, cardiovascular, metabolic, and gynecological fields. With the support of the leading modern traditional Chinese medicine intelligent manufacturing base in China, several previously approved varieties have been fully launched into the market, gaining broad recognition from medical institutions and patients due to their proven efficacy and stable quality.